Cardiome Pharma Corporation Company Profile (NASDAQ:CRME)

About Cardiome Pharma Corporation (NASDAQ:CRME)

Cardiome Pharma Corporation logoCardiome Pharma Corp. (Cardiome) is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of cardiovascular therapies for heart disease. The Company's segments are Europe and Rest of World. Cardiome has two marketed, in-hospital, cardiology products, which include BRINAVESS (vernakalant IV), approved in Europe and other territories for the conversion of onset atrial fibrillation (AF) to sinus rhythm in adults, and AGGRASTAT (tirofiban hydrochloride (HCl)), indicated for use in patients with acute coronary syndrome. Cardiome also commercializes ESMOCARD and ESMOCARD LYO (esmolol hydrochloride), a short-acting beta-blocker used to control heart rate in various cardiovascular indications, in select European markets. Cardiome has also licensed TREVYENT, a development-stage drug device combination product that is under development for pulmonary arterial hypertension, in certain regions outside the United States.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biopharmaceuticals
  • Sub-Industry: N/A
  • Symbol: NASDAQ:CRME
  • CUSIP: N/A
  • Web: www.cardiome.com
Capitalization:
  • Market Cap: $74.02 million
  • Outstanding Shares: 33,801,000
Average Prices:
  • 50 Day Moving Avg: $3.03
  • 200 Day Moving Avg: $3.53
  • 52 Week Range: $2.09 - $4.84
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -3.57
  • P/E Growth: -0.120
Sales & Book Value:
  • Annual Revenue: $23.21 million
  • Price / Sales: 3.17
  • Book Value: $0.85 per share
  • Price / Book: 2.55
Profitability:
  • EBIDTA: ($17,410,000.00)
  • Net Margins: -110.95%
  • Return on Equity: -78.51%
  • Return on Assets: -38.30%
Debt:
  • Debt-to-Equity Ratio: 0.99%
  • Current Ratio: 4.81%
  • Quick Ratio: 4.12%
Misc:
  • Average Volume: 129,473 shs.
  • Beta: 1.1
  • Short Ratio: 5.61
 

Frequently Asked Questions for Cardiome Pharma Corporation (NASDAQ:CRME)

What is Cardiome Pharma Corporation's stock symbol?

Cardiome Pharma Corporation trades on the NASDAQ under the ticker symbol "CRME."

How were Cardiome Pharma Corporation's earnings last quarter?

Cardiome Pharma Corporation (NASDAQ:CRME) announced its earnings results on Tuesday, August, 8th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by $0.08. The firm had revenue of $5.75 million for the quarter, compared to analyst estimates of $6.88 million. Cardiome Pharma Corporation had a negative net margin of 110.95% and a negative return on equity of 78.51%. Cardiome Pharma Corporation's revenue for the quarter was down 2.5% compared to the same quarter last year. During the same period last year, the firm earned ($0.37) earnings per share. View Cardiome Pharma Corporation's Earnings History.

When will Cardiome Pharma Corporation make its next earnings announcement?

Cardiome Pharma Corporation is scheduled to release their next quarterly earnings announcement on Monday, November, 6th 2017. View Earnings Estimates for Cardiome Pharma Corporation.

Where is Cardiome Pharma Corporation's stock going? Where will Cardiome Pharma Corporation's stock price be in 2017?

5 equities research analysts have issued 12-month price objectives for Cardiome Pharma Corporation's shares. Their predictions range from $3.50 to $10.00. On average, they expect Cardiome Pharma Corporation's stock price to reach $6.56 in the next twelve months. View Analyst Ratings for Cardiome Pharma Corporation.

What are analysts saying about Cardiome Pharma Corporation stock?

Here are some recent quotes from research analysts about Cardiome Pharma Corporation stock:

  • 1. Canaccord Genuity analysts commented, "Date and time of first dissemination: August 21, 2017, 09:42 ET Date and time of production: August 21, 2017, 09:42 ET Target Price / Valuation Methodology: Cardiome Pharma Corp. – CRME Discounted cash flow analysis supports an $8 valuation for CRME shares Our discounted cash flow (DCF) analysis leads us to a 12-month valuation of around $8/share for CRME, assuming continued progress on the Brinavess Canada and Xydalba launches along with a potential Trevyent launch in 2019. We estimate a weighted average cost of capital (WACC) of 11.2%, which assumes an 88% equity/total capital structure at a 10.3% cost of equity capital and a 12% debt/total capital structure at a 14% cost of debt. We use a long-term estimated tax rate of 22% and a terminal growth decline of 1% in our analysis. For cash management purposes, our analysis assumes an equity raise in 2H/17 but management has not publicly commented on the possibility of future capital raises. Risks to achieving Target Price / Valuation: Cardiome Pharma Corp. – CRME OUS payers and providers can be more difficult to predict – Given the relative lack of market data compared to the US coupled with a fragmented payer landscape, variability in physician training and standard of care modalities, and different preferences in patient populations in OUS markets, the marketability of a product in these environments can be more difficult to predict than in the US." (8/21/2017)
  • 2. According to Zacks Investment Research, "Cardiome Pharma Corp. is a product-focused cardiovascular drug development company with two clinical drug programs focused on atrial arrhythmia (intravenous and oral dosing), and a pre-clinical program directed at improving cardiovascular function. " (8/11/2017)

Who are some of Cardiome Pharma Corporation's key competitors?

Who are Cardiome Pharma Corporation's key executives?

Cardiome Pharma Corporation's management team includes the folowing people:

  • W. James O'Shea, Independent Chairman of the Board
  • William L. Hunter M.D., President, Chief Executive Officer, Director
  • Justin A. Renz, Chief Financial Officer
  • Sheila M. Grant, Chief Operating Officer
  • David D. McMasters J.D., Corporate General Counsel
  • David C. Dean, Chief Business Development Officer
  • Jennifer Archibald CPA, Chief Business Operations Officer
  • Hugues Sachot, Chief Commercial Officer
  • Richard M. Glickman LL.D., Lead Independent Director
  • Mark H.N. Corrigan M.D., Independent Director

Who owns Cardiome Pharma Corporation stock?

Cardiome Pharma Corporation's stock is owned by many different of institutional and retail investors. Top institutional shareholders include WESTFIELD CAPITAL MANAGEMENT COMPANY LP (16.75%), Westfield Capital Management Co. LP (16.56%), Tamarack Advisers LP (5.64%), Stonepine Capital Management LLC (5.00%), AlphaOne Investment Services LLC (1.98%) and JPMorgan Chase & Co. (0.49%). View Institutional Ownership Trends for Cardiome Pharma Corporation.

Who sold Cardiome Pharma Corporation stock? Who is selling Cardiome Pharma Corporation stock?

Cardiome Pharma Corporation's stock was sold by a variety of institutional investors in the last quarter, including Stonepine Capital Management LLC, Tamarack Advisers LP and PNC Financial Services Group Inc.. View Insider Buying and Selling for Cardiome Pharma Corporation.

Who bought Cardiome Pharma Corporation stock? Who is buying Cardiome Pharma Corporation stock?

Cardiome Pharma Corporation's stock was acquired by a variety of institutional investors in the last quarter, including Westfield Capital Management Co. LP, AlphaOne Investment Services LLC and JPMorgan Chase & Co.. View Insider Buying and Selling for Cardiome Pharma Corporation.

How do I buy Cardiome Pharma Corporation stock?

Shares of Cardiome Pharma Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cardiome Pharma Corporation's stock price today?

One share of Cardiome Pharma Corporation stock can currently be purchased for approximately $2.18.


MarketBeat Community Rating for Cardiome Pharma Corporation (NASDAQ CRME)
Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  151 (Vote Outperform)
Underperform Votes:  143 (Vote Underperform)
Total Votes:  294
MarketBeat's community ratings are surveys of what our community members think about Cardiome Pharma Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Cardiome Pharma Corporation (NASDAQ:CRME) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 4 Buy Ratings
Consensus Rating:Buy (Score: 2.80)
Consensus Price Target: $6.56 (201.72% upside)

Analysts' Ratings History for Cardiome Pharma Corporation (NASDAQ:CRME)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/22/2017HC WainwrightSet Price TargetBuy$10.00HighView Rating Details
8/21/2017Canaccord GenuitySet Price TargetBuy$8.00HighView Rating Details
12/22/2016Leerink SwannInitiated CoverageOutperform$4.75N/AView Rating Details
11/9/2016Bloom BurtonReiterated RatingBuyN/AView Rating Details
10/12/2016MackieReiterated RatingSpeculative Buy -> Hold$5.10 -> $3.50N/AView Rating Details
8/15/2016Brean CapitalReiterated RatingBuy$10.00 -> $7.00N/AView Rating Details
(Data available from 9/22/2015 forward)

Earnings

Earnings History for Cardiome Pharma Corporation (NASDAQ:CRME)
Earnings by Quarter for Cardiome Pharma Corporation (NASDAQ:CRME)
Earnings History by Quarter for Cardiome Pharma Corporation (NASDAQ CRME)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/6/2017        
8/8/20176/30/2017($0.18)($0.26)$6.88 million$5.75 millionViewListenView Earnings Details
5/15/20173/31/2017($0.15)($0.20)$6.96 million$5.19 millionViewN/AView Earnings Details
3/7/2017Q4($0.16)($0.18)$6.72 million$7.00 millionViewListenView Earnings Details
11/7/2016Q316($0.20)($0.19)$5.68 million$5.20 millionViewListenView Earnings Details
8/9/2016Q216($0.19)($0.37)$6.73 million$5.90 millionViewN/AView Earnings Details
5/13/2016Q116($0.21)($0.06)$6.34 million$7.10 millionViewListenView Earnings Details
3/10/2016Q415($0.19)($0.37)$7.74 million$4.70 millionViewListenView Earnings Details
11/13/2015Q315($0.23)($0.31)$7.08 million$5.00 millionViewListenView Earnings Details
8/5/2015Q215($0.25)($0.43)$7.67 million$5.70 millionViewN/AView Earnings Details
5/13/2015Q115($0.28)($0.23)$7.48 million$5.50 millionViewListenView Earnings Details
3/12/2015Q414($0.14)($0.39)$8.54 million$7.00 millionViewN/AView Earnings Details
11/7/2014Q314($0.13)($0.26)$6.20 million$7.81 millionViewN/AView Earnings Details
8/11/2014Q2 2014($0.16)($0.26)$6.77 million$7.67 millionViewN/AView Earnings Details
5/12/2014Q114($0.11)($0.20)$8.08 million$7.60 millionViewN/AView Earnings Details
3/27/2014($0.22)($0.53)ViewN/AView Earnings Details
11/6/2013Q3 13($0.21)($0.29)ViewN/AView Earnings Details
8/2/2013Q2 13($0.19)($0.22)ViewN/AView Earnings Details
5/13/2013Q113$1.48$1.47$1.60 millionViewN/AView Earnings Details
3/15/2013Q412($0.05)$0.13$0.84 millionViewN/AView Earnings Details
11/13/2012Q312($0.11)($0.22)ViewN/AView Earnings Details
11/4/2011($0.10)($0.12)ViewN/AView Earnings Details
5/16/2011($0.11)($0.12)ViewN/AView Earnings Details
3/10/2011($0.08)($0.12)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Cardiome Pharma Corporation (NASDAQ:CRME)
2017 EPS Consensus Estimate: ($0.54)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.12)($0.09)($0.11)
Q2 20172($0.16)($0.14)($0.15)
Q3 20172($0.13)($0.12)($0.13)
Q4 20172($0.17)($0.15)($0.16)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Cardiome Pharma Corporation (NASDAQ:CRME)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Cardiome Pharma Corporation (NASDAQ:CRME)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Cardiome Pharma Corporation (NASDAQ:CRME)
Latest Headlines for Cardiome Pharma Corporation (NASDAQ:CRME)
Source:
DateHeadline
americanbankingnews.com logoCritical Comparison: Cardiome Pharma Corporation (CRME) versus Its Rivals
www.americanbankingnews.com - September 21 at 10:14 AM
americanbankingnews.com logoFinancial Review: Cardiome Pharma Corporation (CRME) and Its Peers
www.americanbankingnews.com - September 17 at 4:26 AM
americanbankingnews.com logoCardiome Pharma Corporation (CRME) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - September 16 at 3:00 PM
finance.yahoo.com logoCardiome Pharma Corp. :CRME-US: Earnings Analysis: Q2, 2017 By the Numbers : September 13, 2017
finance.yahoo.com - September 13 at 6:47 PM
finance.yahoo.com logoCardiome, Pipeline Offers Opportunities Beyond Brinavess
finance.yahoo.com - September 6 at 5:32 PM
americanbankingnews.com logo$7.80 Million in Sales Expected for Cardiome Pharma Corporation (CRME) This Quarter
www.americanbankingnews.com - September 5 at 1:56 AM
americanbankingnews.com logo Brokerages Anticipate Cardiome Pharma Corporation (CRME) Will Announce Earnings of -$0.17 Per Share
www.americanbankingnews.com - September 3 at 10:24 PM
americanbankingnews.com logoValuEngine Downgrades Cardiome Pharma Corporation (CRME) to Strong Sell
www.americanbankingnews.com - September 3 at 4:32 PM
streetinsider.com logoCardiome Pharma (CRME) Says New Data Presented at ESC Highlights Clinical Benefit of BRINAVESS
www.streetinsider.com - August 30 at 6:37 PM
americanbankingnews.com logoCardiome Pharma Corporation (CRME) vs. Kamada (KMDA) Head to Head Contrast
www.americanbankingnews.com - August 29 at 12:22 AM
seekingalpha.com logoCardiome not quite there on resubmission of Brinavess NDA; shares down 5% premarket
seekingalpha.com - August 23 at 4:11 AM
americanbankingnews.com logoCardiome Pharma Corporation (CRME) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - August 22 at 4:56 PM
americanbankingnews.com logoFinancial Comparison: Cardiome Pharma Corporation (CRME) versus VIVUS (VVUS)
www.americanbankingnews.com - August 22 at 10:32 AM
americanbankingnews.com logoCanaccord Genuity Analysts Give Cardiome Pharma Corporation (CRME) a $8.00 Price Target
www.americanbankingnews.com - August 21 at 6:02 PM
americanbankingnews.com logo Brokerages Expect Cardiome Pharma Corporation (CRME) Will Announce Quarterly Sales of $7.80 Million
www.americanbankingnews.com - August 18 at 11:16 AM
americanbankingnews.com logo Analysts Expect Cardiome Pharma Corporation (CRME) Will Announce Earnings of -$0.17 Per Share
www.americanbankingnews.com - August 16 at 10:16 AM
americanbankingnews.com logoCardiome Pharma Corporation (CRME) Cut to Sell at Zacks Investment Research
www.americanbankingnews.com - August 11 at 9:04 PM
americanbankingnews.com logoCormark Analysts Reduce Earnings Estimates for Cardiome Pharma Corporation (NASDAQ:CRME)
www.americanbankingnews.com - August 11 at 9:26 AM
americanbankingnews.com logoCardiome Pharma Corporation (CRME) Releases Earnings Results, Misses Expectations By $0.09 EPS
www.americanbankingnews.com - August 8 at 6:30 PM
americanbankingnews.com logoCardiome Pharma Corporation (NASDAQ:CRME) Scheduled to Post Quarterly Earnings on Tuesday
www.americanbankingnews.com - August 3 at 10:40 AM
americanbankingnews.com logo$6.97 Million in Sales Expected for Cardiome Pharma Corporation (CRME) This Quarter
www.americanbankingnews.com - July 31 at 9:41 AM
americanbankingnews.com logo-$0.18 Earnings Per Share Expected for Cardiome Pharma Corporation (NASDAQ:CRME) This Quarter
www.americanbankingnews.com - July 29 at 7:46 AM
americanbankingnews.com logoCardiome Pharma Corporation (CRME) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - July 28 at 2:31 PM
americanbankingnews.com logoCardiome Pharma Corporation (NASDAQ:CRME) Upgraded at Zacks Investment Research
www.americanbankingnews.com - July 18 at 9:04 PM
finance.yahoo.com logoCardiome Announces Health Canada Approval of AGGRASTAT® High Dose Bolus Regimen
finance.yahoo.com - July 17 at 5:52 PM
americanbankingnews.com logoCardiome Pharma Corporation (CRME) Earns "Buy" Rating from Canaccord Genuity
www.americanbankingnews.com - July 17 at 10:39 AM
americanbankingnews.com logoCardiome Pharma Corporation (NASDAQ:CRME) Cut to "Sell" at Zacks Investment Research
www.americanbankingnews.com - July 11 at 9:04 PM
americanbankingnews.com logo$6.97 Million in Sales Expected for Cardiome Pharma Corporation (NASDAQ:CRME) This Quarter
www.americanbankingnews.com - July 7 at 4:29 PM
americanbankingnews.com logo Analysts Anticipate Cardiome Pharma Corporation (CRME) Will Post Earnings of -$0.18 Per Share
www.americanbankingnews.com - July 5 at 9:12 AM
americanbankingnews.com logoCardiome Pharma Corporation (CRME) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - July 3 at 2:49 PM
americanbankingnews.com logo Brokerages Anticipate Cardiome Pharma Corp (CRME) Will Announce Quarterly Sales of $6.97 Million
www.americanbankingnews.com - June 10 at 7:34 AM
americanbankingnews.com logo-$0.18 Earnings Per Share Expected for Cardiome Pharma Corp (CRME) This Quarter
www.americanbankingnews.com - June 9 at 12:06 AM
americanbankingnews.com logoCardiome Pharma Corp (CRME) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - June 6 at 2:46 PM
americanbankingnews.com logoCardiome Pharma Corp (CRME) Sees Significant Increase in Short Interest
www.americanbankingnews.com - May 21 at 10:26 PM
finance.yahoo.com logoCardiome Pharma Corp. :CRME-US: Earnings Analysis: Q1, 2017 By the Numbers : May 19, 2017
finance.yahoo.com - May 19 at 4:22 PM
finance.yahoo.com logoCardiome Pharma (CRME) Looks Good: Stock Moves 6.1% Higher
finance.yahoo.com - May 18 at 10:54 AM
americanbankingnews.com logoQ2 2017 EPS Estimates for Cardiome Pharma Corp (CRME) Increased by Analyst
www.americanbankingnews.com - May 18 at 8:20 AM
streetinsider.com logoCardiome Pharma (CRME) Names Justin Renz as CFO; Jennifer Archibald Appointed Chief Business Operations Officer
www.streetinsider.com - May 17 at 11:30 AM
finance.yahoo.com logoCardiome (CRME) Q1 Loss Wider Than Expected, Sales Miss
finance.yahoo.com - May 17 at 11:30 AM
americanbankingnews.com logoCardiome Pharma Corp (CRME) Posts Earnings Results, Misses Expectations By $0.05 EPS
www.americanbankingnews.com - May 16 at 4:28 PM
finance.yahoo.com logoCardiome Reports Changes To Senior Management Team
finance.yahoo.com - May 16 at 12:15 PM
finance.yahoo.com logoInvestor Network: Cardiome Pharma Corp. to Host Earnings Call
finance.yahoo.com - May 15 at 4:23 PM
finance.yahoo.com logoCardiome Reports First Quarter 2017 Financial Results
finance.yahoo.com - May 15 at 4:23 PM
finance.yahoo.com logoCardiome reports 1Q loss
finance.yahoo.com - May 15 at 4:23 PM
americanbankingnews.com logo-$0.15 EPS Expected for Cardiome Pharma Corp (CRME) This Quarter
www.americanbankingnews.com - May 12 at 8:28 PM
americanbankingnews.com logoCardiome Pharma Corp (CRME) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - May 12 at 2:58 PM
americanbankingnews.com logoCardiome Pharma Corp (CRME) Lifted to "Hold" at Zacks Investment Research
www.americanbankingnews.com - May 9 at 8:04 PM
finance.yahoo.com logoCardiome To Hold First Quarter 2017 Financial Results Conference Call On May 15
finance.yahoo.com - May 8 at 9:43 AM
americanbankingnews.com logo Analysts Expect Cardiome Pharma Corp (CRME) Will Announce Quarterly Sales of $7.47 Million
www.americanbankingnews.com - April 26 at 2:23 PM
americanbankingnews.com logoZacks: Analysts Expect Cardiome Pharma Corp (CRME) to Post -$0.15 Earnings Per Share
www.americanbankingnews.com - April 24 at 12:28 PM

Social

Chart

Cardiome Pharma Corporation (CRME) Chart for Friday, September, 22, 2017

This page was last updated on 9/22/2017 by MarketBeat.com Staff